0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover206.49%IV-29.44%PremiumDec 20, 2024Expiry Date3.13Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8228Delta0.0461Gamma2.73Leverage Ratio-0.0311Theta0.0032Rho2.24Eff Leverage0.0071Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet